Elevance Health (NYSE:ELV) Updates FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 27.000- for the period, compared to the consensus EPS estimate of 26.890. The company issued revenue guidance of -.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Robert W. Baird raised their target price on Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. TD Cowen upped their price objective on shares of Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Finally, Evercore reaffirmed a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $440.90.

Elevance Health Trading Down 0.3%

NYSE ELV traded down $0.96 during trading hours on Friday, reaching $375.44. The company had a trading volume of 976,884 shares, compared to its average volume of 1,472,493. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $81.42 billion, a P/E ratio of 16.69, a price-to-earnings-growth ratio of 2.17 and a beta of 0.67. The stock has a 50-day moving average of $397.01 and a 200 day moving average of $356.81. Elevance Health has a 1-year low of $273.71 and a 1-year high of $436.24.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The business had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. During the same period last year, the business earned $8.84 earnings per share. The business’s revenue for the quarter was up .8% on a year-over-year basis. As a group, research analysts anticipate that Elevance Health will post 27.04 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a $1.72 dividend. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s payout ratio is presently 30.58%.

Insider Buying and Selling

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Elevance Health

Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of Elevance Health by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after purchasing an additional 1,668,679 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Elevance Health by 27.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after purchasing an additional 1,607,274 shares in the last quarter. Invesco Ltd. increased its stake in Elevance Health by 22.9% during the 3rd quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock worth $839,300,000 after buying an additional 484,303 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Elevance Health by 2.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 2,275,342 shares of the company’s stock worth $797,472,000 after buying an additional 61,472 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its holdings in Elevance Health by 44.2% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock worth $660,935,000 after buying an additional 627,038 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.